Pharmacology and Safety Assessment of Humanized Monoclonal Antibodies for Therapeutic Use *
Preclinical Development Strategies for Novel Gene Therapeutic Products *
Synthetic Oligonucleotides
Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans *
Regulatory Decision Strategy for Entry of a Novel Biologic Therapeutic with a Clinically Unmonitorable Toxicity into Clinical Trials
Safety Assessment of Biotechnology-Derived Pharmaceuticals
Flow Cytometry in the Preclinical Development of Biopharmaceuticals *
Lesions and Identification of Crystalline Precipitates of Glycoprotein IIb-IIIa Antagonists in the Rat Kidney *
Use of In Vivo Confocal Microscopy to Understand the Pathology of Accidental Ocular Irritation *
Molecular Pathology in the Preclinical Development of Biopharmaceuticals *
Development of a Recombinant Interleukin-4-Pseudomonas Exotoxin for Therapy of Glioblastoma *
The Toxicology of Interleukin-12
Preclinical and Early Clinical Development of Keratinocyte Growth Factor, an Epithelial- Specific Tissue Growth Factor *
Development of a Recombinant Growth Factor and Fusion Protein
Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody *
BR96 sFv-PE40 Immunotoxin
Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1 *
Safety Evaluation of Human Living Skin Equivalents *
The Pathologist and Toxicologist in Pharmaceutical Product Discovery *
Revolution through Genomics in Investigative and Discovery Toxicology *
Utilization of Genetically Altered Animals in the Pharmaceutical Industry *
Mechanisms of Disease and Injury
Tumor Models
The Role of IL-10 in Inflammatory Bowel Disease
Animal Models of Arthritis
Preclinical Development of Agents for the Treatment of Osteoporosis *